Objective: Antiretroviral drugs can prevent mother-to-child transmission of HIV infection, but in-utero antiretroviral exposure may be associated with neurologic symptoms due to mitochondrial toxicity. We sought to identify the currently recommended regimen to prevent mother-to-child transmission that optimally balances risks of pediatric HIV infection and neurologic mitochondrial toxicity.
Introduction
The use of antiretroviral drugs to prevent mother-tochild transmission (PMTCT) of HIV infection is one of the most successful achievements in HIV prevention. Following the Pediatric AIDS Clinical Trial Group (PACTG) Study 076 in 1994 [1] , zidovudine (ZDV) monotherapy was widely used for PMTCT, where available [2] . Subsequent trials have investigated antepartum, intrapartum, and postpartum regimens combining ZDV, lamivudine (3TC), nevirapine (NVP), and protease inhibitors [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . MTCT rates have been reduced from more than 25% [1, 17] to less than 2% [4, 8, 18] when potent three-drug antiretroviral therapy (ART) is available and breastfeeding is avoided, and recently reported interventions have reduced transmission to breastfed infants from over 40% (at 24 months of age) [3, 17] to 1-7% (at 6-18 months) [19] [20] [21] [22] [23] [24] [25] [26] .
Most regimens have demonstrated favorable safety profiles for both mothers and infants during the duration of trial follow-up [3, 8, 10, 16, 27] . In 1999, however, French perinatologists reported eight cases of severe cognitive and neurological dysfunction among HIV-negative children after in-utero antiretroviral exposure [28] . These neurologic symptoms, including hypotonia, seizures, encephalopathy, and neuropathy, were similar to both congenital mitochondrial dysfunction in children and antiretroviral-induced mitochondrial toxicity in HIVinfected children and adults [28] . Since this first report, other studies of the effects of in-utero antiretroviral exposure on mitochondrial function in HIV-negative children have differed in methodologies and conclusions [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
Clinicians and policy makers currently recommend PMTCT regimens in the absence of complete data about both the prevalence and severity of mitochondrial toxicity. Although more intensive antiretroviral regimens substantially reduce MTCT among women with low CD4 cell counts, the magnitude of MTCT reduction with three-drug ART compared with shorter-course antiretroviral regimens among women with CD4 cell count more than 200 cells/ml is less well known [11, 22, 26] . It is also unknown whether exposure to more antiretroviral drugs for longer durations or to specific drugs during particular periods of fetal develop-ment causes higher mitochondrial toxicity risk. Because mitochondrial toxicity related to nucleoside reverse transcriptase inhibitors (NRTIs) may be rare and remains controversial, the challenge of identifying the optimal antiretroviral regimen to balance efficacy (reduction in MTCT) with toxicity (pediatric neurologic mitochondrial toxicity) is well suited for assessment by decision analysis [42] . We used the existing data in a decision analytic model to quantify the effects of recommended PMTCT regimens on HIV transmission and neurologic mitochondrial toxicity at 18 months of age for infants in sub-Saharan Africa and to determine the mitochondrial toxicity risk that would warrant a change in current PMTCT recommendations.
Methods
We designed a decision analytic model of pregnant, HIVinfected, ART-naive women in sub-Saharan Africa not meeting 2006 World Health Organization (WHO) criteria for initiation of ART for their own HIV infection (CD4 cell count >200 cells/ml and no history of AIDS) [43] . Using published MTCT and neurologic mitochondrial toxicity risks, we examined the pediatric outcomes at 18 months of age associated with no antiretroviral prophylaxis and with five different recommended PMTCT strategies (Table 1) [43, 44] .
Modeled strategies to prevent mother-to-child transmission For women in resource-limited settings not meeting criteria for ART themselves, WHO recommends four increasingly intensive PMTCT regimens, depending on resource availability [43] . Table 1 outlines the antenatal, intrapartum, and postnatal components of these regimens. We evaluated all WHO-recommended strategies, as well as no antiretroviral drugs (for the purpose of comparison) and protease inhibitor based three-drug ART, as recommended in the United States [44] (Table 1) .
The base-case analysis was performed for breastfeeding mothers without access to elective cesarean section. The effects of formula feeding and of the availability and effectiveness of elective cesarean section on reduction in MTCT were evaluated in sensitivity analyses. Model 28w, 28 weeks of gestational age; 3TC, lamivudine; 6w, 6 weeks; 7d, 7 days; 8-12w, between 8 and 12 weeks of gestational age; ART, antiretroviral therapy; ARVs, antiretrovirals; CBV, 'combivir tail' (7 days of maternal ZDV/3TC); PI, protease inhibitor; PMTCT, prevention of mother-to-child transmission of HIV; sc, short-course (from 28 weeks of gestation); sdNVP, single-dose nevirapine; ZDV, zidovudine.
structure is shown in Fig. 1 . Additional details are provided in the Technical Appendix.
Outcomes/case definitions Neurologic mitochondrial toxicity was defined according to the Enquête Périnatale Française (EPF) clinical case definition, excluding any requirement for radiographic, biochemical, or histological findings [32] (Technical  Appendix) . Intrauterine, intrapartum, and postpartum HIV infections were defined according to the timing of first positive infant virologic test (HIV-1 DNA, RNA, or culture), as typically defined for PMTCT trials [7, 12, 26] . The standard trial definition of intrapartum infection (first positive virologic test between 3 days and 4-8 weeks of age) reflects the limited sensitivity of these assays in the early weeks of life due to delayed viremia [45] , but necessitates the inclusion of early postpartum transmission due to breastfeeding in the 'intrapartum' category.
Model parameters

HIV transmission risk
In the base-case analysis, risks of HIV transmission for each antiretroviral regimen were derived from publications or presentations meeting the following inclusion criteria: clinical trial of a modeled regimen, conducted in Africa, at least 12 months follow-up, and reporting probabilities of HIV infection at each time point among infants who were HIV-negative at the prior time point (or data that permitted these calculations). Clinical trial-based data were used to inform all analyses. With one exception [23] (Technical Appendix), observational reports were excluded because higher rates of loss to follow-up might bias results. Studies meeting most, but not all, inclusion criteria were included in ranges examined in sensitivity analyses (Technical Appendix Table 1 ).
For each HIV transmission time point and antiretroviral strategy, the base-case transmission risk was derived from the most widely accepted or cited estimate (based on expert opinion), aiming for the midpoint of the range of reported transmission risks (Table 2 ) [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . PMTCT data were used to calculate the probability of infection during the intrauterine, intrapartum/early postpartum, and late postpartum periods among children who were uninfected at the previous time point.
MTCT risks were assigned to either breastfed or formulafed strategies according to the predominant feeding practice in each trial. For each breastfed strategy, the median duration of breastfeeding was assumed to be equal to that of the trial population (range for base-case analysis, 9 to >20 months) [3, 17, 27, 47, 49, 54, 55] . We simulated extended breastfeeding in order to generate 18-month results applicable to African populations in which this practice is common, and to conservatively estimate the benefits of peripartum antiretroviral drugs, the protective effects of which are likely to fade with prolonged breastfeeding [27] .
Neurologic mitochondrial toxicity risk
Because an independent risk of fetal mitochondrial dysfunction has been postulated to result from maternal HIV viremia [39, 62] , the base-case analysis derived the risk of mitochondrial dysfunction among HIV-exposed but antiretroviral-unexposed children from the upper confidence limit reported in the EPF cohort: 0 of 1748 antiretroviral-unexposed children, 95% confidence PMTCT and mitochondrial toxicity Ciaranello et al. 2361 Fig. 1 . Structure of a decision analytic model of mother-to-child transmission of HIV. Women who did not meet WHO criteria for initiation of antiretroviral therapy for their own HIV infections were considered eligible for each antiretroviral and feeding strategy.
During the period from 10 weeks of gestation through 18 months postpartum, each of the depicted events occurred based on probabilities derived from the published literature: intrauterine (IU) demise or HIV infection, intrapartum or early postpartum (IP) HIV infection, postpartum (PP) HIV infection, or neurologic mitochondrial toxicity (MT), resulting in the outcomes depicted at the end of each path. [7, 15, 17, 19, 47, 48] (0.031-0.095) [1, 6, 14, [49] [50] [51] [52] [53] 0.07 [7, 15, 17, 19, 47, 48] (0.031-0.095) [1, 6, 14, [49] [50] [51] [52] [53] 0.038 [26] (0.01-0.0389) [3, 8, 11] 0.038 [26] (0.01-0.0389) [3, 8, 11 ] 0.0143 [25] (0.004-0.024) [4, 12, [22] [23] [24] 26] Probability of intrapartum/early postpartum HIV infection 0.139 [17] (0.0903-0.1903) [1, 3, 5, 14, 47, 50, 54, 55 ] 0.046 [15] (0.0392 -0.120) [7, [19] [20] [21] [22] 49 ,53] 0.0376 (0.0376-0.0564) [6, 56] b 0.0259 [11] (0.0059-0.037) [11, 26] 0.0234 (0.003-0.037) [6] b 0.0154 [22] (0.009-0.0177) [24] [25] [26] 57, 58] Probability of postpartum HIV infection 0.0133 [54] (0.0718-0.1823) [3, 5, 17, 47, 55] 0.089 [49] (0.0442-0.0947) [15, 19, 27, 48, 59] 0.085 (0.0249-0.0947)
[56] b 0.045 [26] (0.045-0.0737) [26, 59] 0.04275 (0.03375-0.0737) [26, 56] b 0.0208 [22] (0.009-0.0737) [15, [24] [25] [26] 50, [57] [58] [59] Background probability of pediatric neurologic MT related to maternal HIV 0.0017 [32] (0.0001-0.0289) [39, 60, 61] Additional MT above background
0.0188 [39] (0-0.0290) [39, 40] 0.0188 [39] (0-0.0676) [39, 40] 0.0204 [39] (0-0.0676) [39, 40] Reduction in background risk of MT due to reduction in maternal viremia interval (CI) (0, 0.17%) [32, 63] . Sensitivity analyses evaluated mitochondrial toxicity risks ranging from the general population risk (0.01%) [60, 61] to 2.9%, as reported among antiretroviral-exposed children in PACTG 219/219C [2.9%, 95% CI (0.6%-8.4%)] [39] ( Table 2 ).
The risks of mitochondrial toxicity among HIV-exposed and antiretroviral-exposed children were derived from two studies of living, uninfected children incorporating routine neuropsychiatric assessment [32, 39] . The basecase analysis made use of the mitochondrial toxicity risks associated with exposure to ZDV (1.88%) and ZDV/3TC (2.04%) at any time during pregnancy in the PACTG 219/219C report [39] ( Table 2 ). Sensitivity analyses incorporated the range of risks reported in these two studies: the overall mitochondrial toxicity risk ranged from 0.26% [32] to 1.8% [39] ; when stratified by time of earliest exposure to specific NRTIs, mitochondrial toxicity risks in the PACTG 219/219C cohort ranged from 0.4% (first exposure to 3TC in second trimester) to 6.9% (first exposure to 3TC in third trimester) [39] .
Assumptions
When data to inform HIV transmission and neurologic mitochondrial toxicity risks were incomplete for any PMTCT strategy, we assumed differences in transmission or toxicity risks compared to the most similar strategy, based on individual components of each regimen ( Table 2 ; Technical Appendix). In the base-case analysis, because MTCTrisks among women with CD4 cell count higher than 200 cells/ml were rarely available [22] , we relied on transmission risks from all women participating in the included PMTCT trials (participants reported with CD4 cell count <200 cells/ml: range 5-24%, mean 12.9%). We then used the lowest published transmission risks to create a 'best case' scenario for HIV risk which may better reflect MTCT from women with less advanced disease. Adherence to antiretroviral and feeding strategies was assumed to be equal to that in the trials ( Table 2) .
Sensitivity analyses
Sensitivity analyses were performed on all model parameters and assumptions, including feeding strategy, the availability of elective cesarean section, and all uncertain input parameters ( Table 2 ; Technical Appendix). In order to determine the prevalence of mitochondrial toxicity which would change current practice, we varied the risks of neurologic mitochondrial toxicity associated with each antiretroviral strategy, with individual components of each strategy, and with maternal HIV viremia over published and clinically plausible ranges ( Table 2 ). The highest and lowest published risks of HIV transmission and mitochondrial toxicity were used to create 'best case' and 'worst case' scenarios for each outcome. The disability of mitochondrial toxicity relative to pediatric HIV infection was also evaluated in sensitivity analyses.
Results
Base-case analysis Among breastfeeding women, provision of no antiretroviral drugs is the least effective and least toxic PMTCT strategy (HIV transmission risk of 30.4% and mitochondrial toxicity risk of 0.2%, at 18 months of age). With increasing number and duration of antiretroviral drugs, the 18-month HIV transmission risk declines markedly (to 4.9% with three-drug ART). When antepartum NRTIs are used, mitochondrial toxicity risks rise from 0.2% (no antiretroviral drugs; sdNVP) to 2.0% (both scZDV regimens) and 2.2% (three-drug ART). Despite this increased toxicity, three-drug ART minimizes total adverse events, defined as the sum of HIV infections and mitochondrial toxicity cases ( Table 3 , Section I).
Using population-level estimates, treating 10 000 breastfeeding mothers with the scZDV/sdNVP/CBV regimen (the next most effective and next least toxic regimen) rather than with three-drug ART would prevent 15 cases of mitochondrial toxicity, but would allow 507 additional HIV infections. To substantially reduce mitochondrial toxicity compared to three-drug ART (0.2 vs. 2.2%), one would choose the sdNVP/CBV regimen; this choice would prevent 202 cases of mitochondrial toxicity in the same population, but 1303 additional HIV infections would occur.
Sensitivity analyses
Formula feeding When formula-fed infants are evaluated using other basecase parameters, three-drug ART remains the strategy that minimizes total adverse events ( Table 3 , Section I).
Worst case and best case scenarios
We used the highest published risks of HIV transmission and mitochondrial toxicity associated with each PMTCT regimen to create a 'worst-case' (highest toxicity and lowest efficacy) scenario. In contrast to the base case, if the 'worst case' risks are simultaneously true for both mitochondrial toxicity and HIV, then both scZDV regimens minimize total adverse outcomes compared to three-drug ART in breastfed and formula-fed infants ( Table 3 , Section II). When the 'worst case' estimates are used only for mitochondrial toxicity risk ( Table 3 , Section III), the order of strategies is identical to that in the base case for breastfed infants, but both scZDV regimens are superior to three-drug ART in formula-fed infants. When the 'worst case' estimates are used only for HIV risk, the order of the strategies is unchanged from the base case, regardless of feeding strategy (Technical Appendix).
When 'best case' HIV risks, which may better reflect MTCT risks from mothers with CD4 cell count higher than 200 cells/ml, are combined with base-case mitochondrial toxicity risks, the order of strategies is also unchanged from the base case (Table 3 , Section IV). However, when 'best case' HIV risks and 'worst case' mitochondrial toxicity risks are simultaneously examined, the less-intensive regimens (scZDV/sdNVP/CBV in breastfed infants (Table 3 , Section V), and all antiretroviral regimens in formula-fed infants (Technical Appendix)) minimize total adverse outcomes, compared to threedrug ART.
Relative disability of mitochondrial toxicity and HIV We varied the degree of disability associated with neurologic mitochondrial toxicity as a function of the disability associated with pediatric HIV (Fig. 2 ) and compared the total adverse pediatric outcomes (HIV and mitochondrial toxicity) associated with each strategy. Using the base-case input parameters, we first compared three-drug ART to the most effective regimen that excludes an NRTI, conferring a substantial decrease in toxicity (sdNVP/ CBV). In breastfed infants, the morbidity of mitochondrial toxicity would be more than 6.4 times the morbidity of pediatric HIV infection to recommend the sdNVP/CBV regimen over three-drug ART (open arrow). We then compared three-drug ART to the next most effective and next least toxic regimen (scZDV/sdNVP/CBV). Here, the threshold is higher, because the number of excess cases of HIV that occur when the scZDV/sdNVP/CBV regimen is substituted for three-drug ART greatly exceeds the number of mitochondrial toxicity cases prevented: the morbidity of mitochondrial toxicity would need to be more than 32.1 times that of HIV in breastfed infants in order to recommend the scZDV/sdNVP/CBV regimen over three-drug ART (closed arrow).
Discussion
The efficacy of antiretroviral drugs in the prevention of MTCT of HIV is widely accepted [64] . Two studies report an association between in-utero antiretroviral exposure and infant neurologic dysfunction possibly related to mitochondrial toxicity [32, 39] , but the true prevalence and severity of this postulated mitochondrial toxicity remain controversial [65, 66] . Motivated by the possibility that the association between antiretroviral exposure and mitochondrial toxicity is causal [39] , we conducted an exploratory analysis in order to determine the prevalence and severity of mitochondrial toxicity at which current antiretroviral recommendations for PMTCT would merit change [43, 44] . risks. Overall, three-drug ART initiated in the first trimester results in many fewer pediatric HIV infections, slightly more cases of pediatric neurologic mitochondrial toxicity, and substantially fewer total adverse pediatric outcomes (HIV infections and mitochondrial toxicity cases) than the less toxic but less effective regimens.
Published studies of antiretroviral-associated mitochondrial toxicity have differed in methodology and mitochondrial toxicity case definition, which may explain inconsistent findings [2, 5, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 40, [73] [74] [75] [76] [77] [78] . In addition, most studies have not controlled for maternal substance abuse and socioeconomic factors [77] , high maternal viral load [50] , and maternal disease stage [39] , all of which have been hypothesized to cause infant mitochondrial dysfunction and adverse neurologic outcomes [39, 62, 77] . We therefore chose data from the only two studies using routine neuropsychiatric evaluations of living, HIV-uninfected children [32, 39] . Brogly et al. [39] demonstrated a significantly higher risk of mitochondrial toxicity when NRTIs (ZDV, 3TC, or both) were initiated in the third trimester than when they are initiated in the first trimester. They postulate a period of neurodevelopment late in gestation in which the fetal brain is uniquely sensitive to NRTI-induced mitochondrial toxicity [79] [80] [81] . The authors were unable to control for high maternal RNA at delivery (likely a result of late antiretroviral initiation) and maternal drug use (a potential cause of late antiretroviral initiation, although not associated with mitochondrial toxicity in this study). Because these factors may have led to the overestimation of mitochondrial toxicity risk from third-trimester NRTI initiation, our base-case analysis conservatively relied on the mitochondrial toxicity risk associated with any ZDV, 3TC, or ZDV/3TC exposure, regardless of timing (1.88-2.04%).
Our results demonstrate that at mitochondrial toxicity prevalences lower than the base-case risks (as in the EPF, range 0.26-0.87%) [32] , three-drug ART would still minimize total adverse outcomes. More importantly, these results remain true at mitochondrial toxicity prevalences higher than the base-case scenario. Our 'worst-case' mitochondrial toxicity scenario used data from subgroups with third-trimester initiation of ZDV, 3TC, or ZDV/3TC in PACTG 219/219C; results suggest that even if these 'worst-case' mitochondrial toxicity estimates were correct, a change in recommended antiretroviral drugs for PMTCT would be warranted only if the very highest or lowest published HIV risks associated with each regimen were also true. HIV transmission risks at 18 months in the 'best case' and 'worst case'scenarios are well outside commonly reported ranges [1, 8, 18, 23, 26, 57, 69] .
Currently reported prevalences of mitochondrial toxicity are therefore unlikely to change PMTCT recommendations. However, little is known about the morbidity and mortality of antiretroviral-associated neurologic mitochondrial toxicity [32, 39, 40, 65] , and prognostic information must be extrapolated from reports of congenital mitochondrial dysfunction [60, 61, 82, 83] . As new data specific to antiretroviral-associated mitochondrial toxicity emerge [4, 32, 39, 40, 65, 84] , a primary factor in the choice of PMTCT regimen will be the relative disability of mitochondrial toxicity compared to that of pediatric HIV infection. Pediatric HIV disease substantially reduces life expectancy in sub-Saharan Africa, even when therapy is available [85] [86] [87] [88] , and may itself be associated with significant neurodevelopmental delay [89] . If pediatric HIV infection consistently causes greater morbidity and mortality than does mitochondrial toxicity, then the balance of risk and benefit will always favor more effective regimens for PMTCT. If, however, mitochondrial toxicity is markedly more disabling than pediatric HIV (e.g., if effective therapies for pediatric HIV become widely available), then policy makers may choose PMTCT strategies that permit more cases of HIV infection in order to avoid mitochondrial toxicity in uninfected children.
The combined outcome of HIV infections and mitochondrial toxicity cases allowed us to estimate that, at basecase mitochondrial toxicity risks, neurologic mitochondrial toxicity would need to be at least 6.4 times more disabling than HIV infection in order to prompt a change in current PMTCT recommendations.
Of note, this model did not examine maternal outcomes. Emerging data suggest a benefit to ART initiation at CD4 cell count higher than 200 cells/ml, as reflected in recent changes to US treatment guidelines [90] . Therefore, women included in our model are likely to benefit from three-drug ART during pregnancy, and the effects on maternal health of withdrawing ART after use for PMTCT remain unknown [44, 91, 92] . Maternal drugresistant HIV resulting from single-drug or dual-drug PMTCT regimens may also result in reduced efficacy of ART when it is eventually initiated [93] . These maternal effects may tip the balance of risk and benefit in favor of three-drug ART when both maternal and pediatric outcomes are considered. Additionally, the model did not incorporate the costs of each PMTCT regimen or of clinical care for HIV-affected or mitochondrial toxicity affected children after birth. In settings with severely constrained healthcare resources, concerns for costs may outweigh concerns for toxicity in the selection of antiretroviral regimens for PMTCT.
This analysis required several simplifying assumptions. First, data are limited on late postpartum transmission rates by actual infant feeding practices [7, 17, 68] . Second, the model did not account for the neurodevelopmental effects of maternal age, preterm delivery, or stage of maternal HIV disease, which may affect pediatric neurologic outcomes [94] . Finally, women with CD4 cell count less than 200 cells/ml merit three-drug ART for their own HIV infections as well as for PMTCT [43] , and therefore were intentionally excluded from the model. Because available MTCT data were not limited to women with high CD4 cell counts, the base-case analysis likely overestimates transmission risks for women not requiring ART themselves [19, 95] .
The 'best case' scenario, in which the lowest published HIV transmission risks were attributed to each regimen, may more closely approximate true MTCT risks from women with less advanced disease. The results of the 'best case' HIV scenario were unchanged from the base case, except when the highest published mitochondrial toxicity risks for three-drug ART were simultaneously considered. For breastfed infants in this 'best case HIV/ worst case mitochondrial toxicity' scenario, scZDV/ sdNVP/CBV was superior to three-drug ART, due primarily to the high mitochondrial toxicity risk assigned to third-trimester 3TC exposure. For formula-fed infants, all antiretroviral regimens were superior to three-drug ART due to very low HIV risks assigned to less-intensive regimens. The small differences in total adverse outcomes between strategies suggest that further studies are required to confirm whether scZDV regimens are effective among women with CD4 cell count higher than 200 cells/ml, and whether mitochondrial toxicity risks with three-drug ART approach those observed in the highest-risk subgroups of PACTG 219/219C [39] . If such data emerge and are simultaneously true, shortcourse regimens may be appropriate alternatives to threedrug ART in women with high CD4 cell counts, especially when formula feeding is feasible.
In resource-limited settings, concerns for toxicity, as well as for cost, may influence the selection of less-effective antiretroviral regimens for PMTCT than are recommended in developed nations [43] . Currently available data suggest that total pediatric adverse outcomes (HIV infections and cases of neurologic mitochondrial toxicity) are minimized by the use of protease inhibitor-based three-drug ART for PMTCT. Less-effective antiretroviral regimens would only be substantially superior to three-drug ART if the very highest or lowest published risks of HIV, as well as the highest published risks of mitochondrial toxicity, associated with each strategy were simultaneously true, or if antiretroviral-related mitochondrial toxicity were markedly more disabling than pediatric HIV infection. Access to diagnosis, prenatal care, and antiretroviral drugs for HIV-infected women in resource-limited settings remain crucial to reducing the more than 500 000 perinatal infections that occur worldwide each year, and every effort should be made to provide three-drug ART to women who require therapy for their own health [64] . For women with less advanced HIV disease, nucleoside-sparing PMTCT regimens, or regimens that avoid combination nucleosides, may warrant further investigation. In the meantime, currently reported risks of mitochondrial toxicity should not lead providers or patients to avoid the use of threedrug ART during pregnancy for PMTCT, and efforts should be expanded to increase the availability of threedrug ART for PMTCT in resource-limited settings.
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INTRODUCTION
This technical appendix is intended to provide methodologic details to supplement the description of the methods in the manuscript text. We also include some additional model output and results.
Methods
Model parameter and assumptions
Cesarean sections Because elective cesarean sections were rare in the studies providing transmission data (<21% in resource-limited settings, even in clinical trial sites) [1] [2] [3] [4] [5] [6] [7] , and because the majority of HIVinfected women in sub-Saharan Africa lack access to routine cesarean section [8, 9] , we assumed that this procedure was not available. In sensitivity analyses, the availability of cesarean section and the effectiveness of this procedure on reducing intrapartum transmission were varied together from 0 to 30%, based on reported risk reductions and incorporating the most widely cited odds ratio of 0.5) [10] . The same degree of reduction in intrapartum HIV transmission was attributed to elective cesarean sections performed with any of the ARV strategies. In reality, elective cesarean delivery is likely to be more protective in the presence of high maternal HIV RNA at delivery, which is expected to occur more frequently with less intensive ARV strategies [11] . This assumption biases the results of the analysis against the efficacy of 3-drug ART for PMTCT (consistent with our goal of a conservative estimate of this efficacy).
Case definitions
Intrauterine HIV infection was defined as a positive infant virologic test (HIV-1 DNA, RNA, or culture) within 3 days of birth. Intrapartum infection was defined as a first positive virologic test between 3 days and 4-8 weeks of age. Postpartum infection was defined as either a negative virologic test at 4-8 weeks of age followed by a positive virologic test at any time, or a positive serologic test (ELISA, confirmed by Western blot) after 12 months of age. While in practice, children may not be tested at these specific time points, the model requires data to simulate biologic events at rates reported in the trials, rather than clinical information available to providers.
Neurologic MT was defined according to the Enquête Périnatale Française (EPF) clinical case definition, excluding any requirement for radiographic, biochemical, or histological findings [12] . As in PACTG 219/219C, no child whose sole criterion for neurologic MT was severe cognitive delay was included in the base case [13] , although the effects of including such children were evaluated in sensitivity analyses. The EPF criteria were selected in place of other published diagnostic criteria (such as the Mitochondrial Disease Criteria [14] ) because they were specifically constructed to reflect mitochondrial damage related to ARV exposure.
HIV transmission risks
We identified all published and unpublished reports of each modeled ARV strategy in order to derive MTCT risks for use in the model (Appendix Table 1 ). Clinical trials were included if they met the following criteria: conducted in Africa, at least 12-month follow-up duration, and documenting conditional probabilities of HIV transmission at each time point (probability of infection among infants who were HIV-negative at the previous time point) or presenting data in such a way as to permit calculation of these probabilities. Reports not meeting all inclusion criteria were included in sensitivity analyses (Appendix Table 1 ). Observational data from the DREAM study [15] were used to inform the MTCT risk from formula-feeding women on HAART. This report was chosen because it supplied the only African data specific to this strategy, and because reported transmission risks (despite potential loss to follow-up) were higher than the alternative trial-based reports from the US and Europe [16, 17] .
For each HIV transmission time point (intrauterine, intrapartum/early postpartum, and late postpartum infection) and ARV strategy, the base case transmission risk was derived from the most widely accepted or cited estimate (based on expert opinion), aiming for the midpoint of the range of reported HIV transmission risks. All data sources are presented in Appendix Table 1 . The base case analysis relied on a conservative assumption that the risk of late postpartum transmission to formula-fed infants was zero.
When data were not available at each time point for the specific combinations of ARVs in each WHO-recommended regimen (particularly, sdNVP/CBV, scZDV and scZDV/CBV regimens), we derived the base case transmission risks by modifying the published risks attributed to the most similar regimen. For example, probability of intrauterine transmission was assumed to be equal for all regimens with no antenatal ARVs [5] . Intrapartum transmission in the scZDV/CBV breastfed strategy was assumed to be similar to that in the scZDV breastfed strategy; we then reduced it by a factor representing a slight decrease in intrapartum/early breastfeeding transmission due to the small reduction in maternal viral load that might result from the administration of intrapartum ZDV/3TC. This factor, derived from a trial in which tenofovir/emtricitabine (rather than ZDV/3TC) showed a statistically nonsignificant reduction in transmission risk of 0.8 [18] , was varied in sensitivity analyses. As no data were available from African trials of ZDV from 28 weeks of gestation, we used data from trials of ZDV between 32 and 36 weeks of gestation with intrapartum NVP; lower published estimates were used in the base case to simulate earlier ZDV initiation, and higher estimates were retained in the sensitivity analyses [3, 19] . Data for the 3-drug ART strategy in breastfeeding women were taken primarily from the Kisumu Breastfeeding Study [20] , although intrauterine risk was derived from the AMATA study because of earlier ART initiation during pregnancy that more closely followed the modeled regimen [21] . There are no data on breastfeeding transmission following 3drug ART during pregnancy in the absence of ongoing ART during lactation. Because rates of postnatal transmission with the modeled 3-drug ART strategy (ART cessation after delivery) are likely to be greater than those seen in many available studies, the base case analysis used the higher range of available estimates (from the Kisumu Breastfeeding Study [20] , with greater postpartum transmission than seen in AMATA [21] , Mashi [2] , or DREAM [15] ), and sensitivity analyses on the 'best case' HIV risks were conducted. Although transmission following ART is likely to be lower than following the scZDV regimens, due to the reduction in viral load associated with six months of ART during pregnancy [22] , in the 'worst case' scenario, we assumed that the viral load reduction associated with 3-drug ART during pregnancy would have no effect on reducing transmission after delivery [23] .
All HIV transmission risks and modifying assumptions were tested in sensitivity analyses.
Neurologic MT risks
Detailed descriptions of the input data and assumptions regarding MT risk associated with each regimen are provided in Appendix Table 1 . MT risks were assumed to accrue equally to HIVinfected and -uninfected children, as there are no published estimates of the degree to which HIVinfected children may experience higher rates of mitochondrial dysfunction than HIV-negative children [13, 24] .
Results
Sensitivity analyses
Formula feeding When formula-fed infants are evaluated using all other parameters as in the base case, provision of no ARVs for PMTCT remains the least effective and least toxic strategy Appendix [5, 6, 27, [29] [30] [31] [32] 0.031-0.095 [6, [25] [26] [27] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Equal to breastfed infants sdNVP 0.07 [5, 6, 27, [29] [30] [31] [32] 39] 0.031-0.095 [6, [25] [26] [27] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Equal to breastfed infants sdNVP/CBV 0.07 [5, 6, 27, [29] [30] [31] [32] 0.031-0.095 [6, [25] [26] [27] [29] [30] [31] [32] [33] [34] 37, 38] Equal to breastfed infants scZDV/sdNVP 0.038 [2, 3] 0.01-0.0389 [1, 19] Equal to breastfed infants scZDV/sdNVP/CBV 0.038 [2, 3] 0.01-0.0389 assumption: identical antepartum regimen to scZDV/sdNVP Equal to breastfed infants 3-drug ART 0.0143 [21] 0.004-0.024 [2, [15] [16] [17] 20, 40] Equal to breastfed infants Probability of intrapartum/early postpartum HIV infection No ARVs 0.139 [27, 32] 0.0903-0.1903 [19, 22, 26, 31, 41, 42] 0.1125 [31] (0.0681-0.135) [26, 27, 32 ] sdNVP 0.046 [5] 0.0392-0.120 [6, 20, 29, [37] [38] [39] 43] 0.0366 [5] (0.03-0.0366) [ [20] 0.009-0.0177 [2, 15, 17, 21, 40, 44] 0.009 [15] (0.0048-0.009) [2, 16, 17 ] Probability of postpartum HIV infection No ARVs 0.133 [22] 0.0718-0.1823 [19, 27, 31, 41, 42] 0 (Assumption) [33] (0-0.107) [2, 5, 27 ] sdNVP 0.089 [38] 0.0442-0.0947 [5, 23, 29, 30, 38, 45] 0 (Assumption) [33] (0-0.02) [2,5] sdNVP/CBV (0.95) M sdNVP (0.75-1.0) M sdNVP 0 (Assumption) [33] (0-0.02) [5] Assumption: reduction in PP transmission related to 7 days of ZDV/3TC given PP to BF mother [18] scZDV/sdNVP 0.045 [2] 0.045-0.0737 [2, 23] 0 (Assumption) [33] (0-0.0081) [2] scZDV/sdNVP/CBV (0.95) M scZDV/sdNVP (0.75-1.0) MscZDV/sdNVP 0 (Assumption) [33] (0-0.0081) [2] Assumption: reduction in PP transmission related to 7 days of ZDV/3TC given PP to BF mother [18] 3-drug ART 0.0208 [20] 0.009-0.0737 [2, 21, 23, 40, 44, 46] 0 (Assumption) [33] (0-0.0081) [2, 16, 17, 46] Probability of neurologic mitochondrial toxicity Background risk for MT (general population) 0.0001 [47, 48] Applied to all strategies Equal to breastfed infants No ARVs (background risk due to maternal HIV) 0.0017 [12] 0.0001-0.0289 [13, 47, 48] Equal to breastfed infants Table  3 ). With increasing number and duration of ARV drugs, the HIV transmission risk again declines markedly (to 2.3% with 3-drug ART), and the MT risk again increases moderately to 2.19%. The advantage of progressively more effective PMTCT is therefore slightly smaller among a cohort of 10 000 formula-feeding mothers than among breastfeeding mothers. The choice of the next most effective regimen (scZDV/sdNVP/CBV) over 3drug ART would again prevent 15 cases of MT, but now would lead to only 201 HIV infections. The choice of the most effective regimen that excludes antepartum nucleoside analogues (sdNVP/CBV) in place of 3-drug ART would again prevent 202 cases of MT, but 748 HIV infections would occur. Three-drug ART remains the strategy that minimizes total adverse events (MT cases plus HIV infections) among formula-fed infants.
Worst-and best-case scenarios
We used the highest published risks of MTassociated with each PMTCT regimen to create a 'worst-case' scenario for MT, and the highest risks of HIV transmission reported with each regimen to create a 'worst-case' scenario for HIV. These scenarios reflect the greatest reported toxicity and lowest reported efficacy for each PMTCT regimen. Results for simultaneous 'worstcase' estimates of both HIVand MTrisk, and for MTrisk alone, are described in the manuscript (Manuscript Table 3 ). Because the published 'worst-case' HIV and MT risks associated with 3-drug ART are more different from the base case than are the published 'worst-case' estimates associated with the other regimens, combining both 'worst-case' scenarios causes sufficient change from the base case to make the scZDV/sd, and scZDV/sdNVP/ CBV regimens superior to 3-drug ART in both formulaand breast-fed infants. When 'worst-case' estimates are used only for HIV risk, the order of the strategies is not changed from the base case in formula-or breastfed infants (Appendix Table 2 , top). When 'worst-case' estimates are used only for MT risk, the order of strategies is equal to that in the base case for breastfed infants, but the scZDV/sdNVP and scZDV/sdNVP/CBV regimens are superior to 3-drug ART in formula-fed infants (Manuscript Table 3 ).
We used the lowest published HIV transmission and MT risks to create a 'best-case' (greatest efficacy and least toxicity) scenario. When the 'best-case' risks are used for HIV alone, the order of the ARV strategies is again not changed from the base case (Manuscript Table 3 , Section IV). However, when 'best case' HIV risks and 'worst case' MT risks are simultaneously examined in breastfed infants, scZDV/sdNVP/CBV minimizes total adverse outcomes (Manuscript Table 3 , Section V). This is because, relative to the base case, the 'worst-case' MT risk for 3-drug ART increases by an amount (from 2.2 to 9.6%, due primarily to 3rd-trimester 3TC exposure) that is greater than the reduction in HIV risk (from 4.9 to 1.3%); this allows scZDV/sdNVP/CBV (MT risk rises from 2.2 to 5.8%, while HIV risk decreases from 10.0 to 4.6%) to minimize adverse outcomes compared to 3-drug ART. In formula fed infants, all ARV regimens minimize total adverse outcomes compared to 3-drug ART (Manuscript Table 3 , Section IV).
Because the 'best-case' MT risks for each regimen assign no additional toxicity above the general population risk to each ARV regimen, combining the 'best-case' MT estimates with any HIV risk estimate generates estimates of total morbidity (HIV plus MT) that are essentially equal to the HIV estimates alone (results not shown). Varying the HIVor MTrisk of any regimen individually leads each regimen to become superior to the next-best regimen when HIV risk is less than, or MT risk greater than, the risk assigned to the next-best regimen.
Neurologic MT associated with single-dose nevirapine and protease inhibitor exposure In the base case scenario, no MT risk is attributed to the administration of sdNVP or continuous protease inhibitors (PIs) to mothers or neonates. In sensitivity analyses, at PMTCT/Mitochondrial Toxicity Technical Appendix Ciaranello et al. 5
Appendix Results of analyses using highest published risks for HIV and MT simultaneously, highest risks for HIV and MT alone, and lowest risks for HIV, are shown in the manuscript (Manuscript Table 3 ). Because the lowest published MT risks for each regimen were assumed to be 0, analyses combining the lowest published MT risks with any level of HIV risk generate estimates essentially equal to the HIV estimates alone. all possible probabilities of MT due to sdNVP use, 3drug ART remains superior to the sdNVP-containing regimens (sdNVP/CBV, scZDV/sdNVP, and scZDV/ sdNVP/CBV, and sdNVP) in minimizing total adverse outcomes. If the risk of MT associated with sdNVP exceeded 11.4% in breastfed infants, or 7.0% in formula-fed infants, provision of no ARVs would minimize total adverse events relative to the NVPcontaining regimens. This threshold would be different if 3-drug ART were NVP-based, as is often the case in resource-limited settings. When 3-drug ART is PIbased, the risk of MT associated with PI use would need to exceed 5.0% in breastfed infants, or 1.9% in formulafed infants, for the next most effective regimen that excludes a PI (scZDV/sdNVP/CBV) to replace 3-drug ART as the strategy that minimizes total number of adverse events.
Relative disability of MT compared to pediatric HIV infection
Results of varying the disability of MT relative to pediatric HIV infection in the base-case scenario are shown in Manuscript Figure 2 , as well as in Appendix Table 3 (left), and indicate that neurologic MT must always be more disabling than pediatric HIV in order to consider any regimen in place of 3-drug ART. However, in the combined worst-case scenario for both HIV and MT risks (Appendix Table 3 , right), HIV infection must instead be more disabling than MT for 3-drug ART to remain superior to the scZDV/sdNVP and scZDV/ sdNVP/CBV regimens among both breast-and formulafed infants. Among breastfed infants, if MTwere 0.8-fold less morbid than HIV (or, equivalently, if HIV were 1.25 times more morbid than MT), scZDV/sdNVP would minimize total adverse outcomes; if MTwere 0.6-fold less morbid (or HIV 1.67 times more morbid), scZDV/ sdNVP/CBV would minimize total adverse outcomes. Similarly, both scZDV/sdNVP and scZDV/sdNVP/CBV would minimize total adverse outcomes among formulafed infants if MT were 0.5-fold less morbid than HIV (or HIV twice as morbid as MT).
Other assumptions tested in sensitivity analysis Varying the following parameters over plausible ranges had no effect on the main conclusions: the effect of the reduction in maternal viremia on reduction in background MT, the impact of elective cesarean section on reduction in intrapartum HIV transmission, the effect of feeding strategy on relative increase or decrease in early postpartum transmission rates associated with the sdNVP/CBV strategy (for which breastfeeding rates were not published), the effect of intrapartum ZDV/3TC on intrapartum HIV transmission, the effect of postpartum maternal ZDV/3TC on breastfeeding HIV transmission in the CBVcontaining regimens, and the impact on MT risk of intrapartum and breastmilk exposure to individual drugs.
Appendix Table 3 . Disability of neurologic MT relative to pediatric HIV infection above which each ARV strategy minimizes total adverse outcomes (HIV+MT) compared to 3-drug ART. 
